30 Day Trial

Anika Therapeutics Reports 1Q19 Orthobiologic Revenue of $21.7MM, +11.6% vs. 1Q18

Share:

Anika Therapeutics posts 1Q19 orthobiologic revenue of USD $21.7MM, +11.6% vs. 1Q18.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.